JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB23755

Anti-HLA Class I antibody [W6/32] - BSA and Azide free

4

(5 Reviews)

|

(19 Publications)

Anti-HLA Class I antibody [W6/32] - BSA and Azide free (ab23755) is a mouse recombinant monoclonal antibody provided in a PBS only buffer for easy conjugation detecting HLA Class I in Flow Cytometry, IHC-Fr, ICC/IF. Suitable for Human.

- BSA, sodium azide, and glycerol-free for easy conjugation
- Biophysical QC for unrivalled batch-batch consistency
- Over 10 publications
- Trusted since 2005

View Alternative Names

HLAA, HLA-A, Human leukocyte antigen A

4 Images
Immunohistochemistry (Frozen sections) - Anti-HLA Class I antibody [W6/32] - BSA and Azide free (AB23755)
  • IHC-Fr

Supplier Data

Immunohistochemistry (Frozen sections) - Anti-HLA Class I antibody [W6/32] - BSA and Azide free (AB23755)

This data was developed using ab22432, the same antibody clone in a different buffer formulation.

Immunohistochemical analysis of ab22432 10% paraformaldehyde fixed endothelial cells in frozen Human spleen tissue Human heart tissue labeling HLA Class I with ab22432 at 0.05µg/ml. Detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.

Flow Cytometry - Anti-HLA Class I antibody [W6/32] - BSA and Azide free (AB23755)
  • Flow Cyt

Supplier Data

Flow Cytometry - Anti-HLA Class I antibody [W6/32] - BSA and Azide free (AB23755)

This data was developed using ab22432, the same antibody clone in a different buffer formulation.

Flow cytometry overlay histogram showing left Jurkat positive cells and right negative K562 cells stained with ab22432 (red line). The cells were incubated in 1x PBS containing 10 % normal goat serum to block non-specific protein-protein interaction followed by the antibody (ab22432) (1x10^6 in 100 μl at 0.2 μg/ml) for 30 min on ice. The secondary antibody Goat anti-mouse IgG H&L (Alexa Fluor® 488, pre-adsorbed) (ab150117) was used at for 30 min on ice. Isotype control antibody (black line) was mouse IgG2aκ (ab18413) used at the same concentration and conditions as the primary antibody. Unlabeled sample (blue line) was also used as a control. Acquisition of >5000 events were collected using a 50 mW Blue laser (488nm) and 525/40 bandpass filter.

Immunocytochemistry/ Immunofluorescence - Anti-HLA Class I antibody [W6/32] - BSA and Azide free (AB23755)
  • ICC/IF

Supplier Data

Immunocytochemistry/ Immunofluorescence - Anti-HLA Class I antibody [W6/32] - BSA and Azide free (AB23755)

This data was developed using ab22432, the same antibody clone in a different buffer formulation.

Immunofluorescent analysis of 4% Paraformaldehyde-fixed, 0.1% PBS-Tween permeabilized negative cell line K562 labelling HLA Class I with ab22432 at 1µg/mL, blocked with 1% BSA/10% normal goat serum/0.3M glycine in 0.1%PBS-Tween for 1h. The cells were then incubated overnight at 4°C with ab227805 at 5μg/ml and ab6046, Rabbit polyclonal to beta Tubulin - Loading Control. Cells were then incubated with ab150117, Goat polyclonal Secondary Antibody to Mouse IgG H&L (Alexa Fluor® 488) preadsorbed at 1/1000 dilution (shown in green) and ab150080, Goat polyclonal Secondary Antibody to Rabbit IgG - H&L (Alexa Fluor® 594) at 1/1000 dilution (shown in red). Nuclear DNA was labelled with DAPI (shown in blue). Also suitable in cells fixed with 100% methanol (5 min). Image was acquired with a confocal microscope (Leica-Microsystems TCS SP8) and a single confocal section is shown.

Immunocytochemistry/ Immunofluorescence - Anti-HLA Class I antibody [W6/32] - BSA and Azide free (AB23755)
  • ICC/IF

Supplier Data

Immunocytochemistry/ Immunofluorescence - Anti-HLA Class I antibody [W6/32] - BSA and Azide free (AB23755)

This data was developed using ab22432, the same antibody clone in a different buffer formulation.

Immunofluorescent analysis of 4% Paraformaldehyde-fixed, 0.1% PBS-Tween permeabilized HeLa (human cervical adenocarcinoma epithelial cell) cells labelling HLA Class I with ab22432 at 1µg/mL, blocked with 1% BSA/10% normal goat serum/0.3M glycine in 0.1%PBS-Tween for 1h. The cells were then incubated overnight at 4°C with ab92494 at 1µg/mL and ab6046, Rabbit polyclonal to beta Tubulin - Loading Control. Cells were then incubated with ab150117, Goat polyclonal Secondary Antibody to Mouse IgG H&L (Alexa Fluor® 488) preadsorbed at 1/1000 dilution (shown in green) and ab150080, Goat polyclonal Secondary Antibody to Rabbit IgG - H&L (Alexa Fluor® 594) at 1/1000 dilution (shown in red). Nuclear DNA was labelled with DAPI (shown in blue). Image was acquired with a high-content analyser (Operetta CLS, Perkin Elmer) and a maximum intensity projection of confocal sections is shown.

  • 578 PE

    PE Anti-HLA Class I antibody [W6/32]

  • HRP

    HRP Anti-HLA Class I antibody [W6/32]

  • Biotin

    Biotin Anti-HLA Class I antibody [W6/32]

Key facts

Host species

Mouse

Clonality

Monoclonal

Clone number

W6/32

Isotype

IgG2a

Carrier free

Yes

Reacts with

Human

Applications

Flow Cyt, ICC/IF, IHC-Fr

applications

Immunogen

Tissue preparation containing HLA-A protein. The exact immunogen used to generate this antibody is proprietary information.

P04439

Specificity

The antibody recognises HLA-A, HLA-B and HLA-C.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCFr" : {"fullname" : "Immunohistochemistry (Frozen sections)", "shortname":"IHC-Fr"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCFr-species-checked": "testedAndGuaranteed", "IHCFr-species-dilution-info": "", "IHCFr-species-notes": "<p></p>", "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "<p></p>", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "<p></p>" } } }

Product details

What is this antibody validated in?
Anti-HLA Class I antibody [W6/32] - BSA and Azide free (ab23755) is a mouse recombinant monoclonal antibody and is validated for use in Flow Cytometry (Flow Cyt), Immunohistochemistry (IHC-Fr), Immunocytochemistry/immunofluorescence (ICC/IF) in Human samples.

Trusted by the scientific community
Anti-HLA Class I [W6/32] - BSA and Azide free (ab23755) was first used in a scientific publication in 2005 and has been cited over 10 times in peer-reviewed journals.

Reviewed by scientists
Anti-HLA Class I [W6/32] - BSA and Azide free (ab23755) has over 5 independent reviews from customers.

Other related products
We have a range of other formats of antibody clone [W6/32] also available for your convenience: ab22432, Carrier free - ab23755, HRP - ab33256, PE - ab33257, Biotin - ab110665, ab155381

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Constituents: 100% PBS
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
Storage information
Do Not Freeze

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Antigen-presenting major histocompatibility complex class I (MHCI) molecule. In complex with B2M/beta 2 microglobulin displays primarily viral and tumor-derived peptides on antigen-presenting cells for recognition by alpha-beta T cell receptor (TCR) on HLA-A-restricted CD8-positive T cells, guiding antigen-specific T cell immune response to eliminate infected or transformed cells (PubMed : 10449296, PubMed : 12138174, PubMed : 12393434, PubMed : 1402688, PubMed : 15893615, PubMed : 17189421, PubMed : 19543285, PubMed : 21498667, PubMed : 24192765, PubMed : 24395804, PubMed : 2456340, PubMed : 2784196, PubMed : 28250417, PubMed : 7504010, PubMed : 7694806, PubMed : 9862734). May also present self-peptides derived from the signal sequence of secreted or membrane proteins, although T cells specific for these peptides are usually inactivated to prevent autoreactivity (PubMed : 25880248, PubMed : 7506728, PubMed : 7679507). Both the peptide and the MHC molecule are recognized by TCR, the peptide is responsible for the fine specificity of antigen recognition and MHC residues account for the MHC restriction of T cells (PubMed : 12796775, PubMed : 18275829, PubMed : 19542454, PubMed : 28250417). Typically presents intracellular peptide antigens of 8 to 13 amino acids that arise from cytosolic proteolysis via IFNG-induced immunoproteasome or via endopeptidase IDE/insulin-degrading enzyme (PubMed : 17079320, PubMed : 17189421, PubMed : 20364150, PubMed : 26929325, PubMed : 27049119). Can bind different peptides containing allele-specific binding motifs, which are mainly defined by anchor residues at position 2 and 9 (PubMed : 7504010, PubMed : 9862734).. Allele A*01 : 01 : Presents a restricted peptide repertoire including viral epitopes derived from IAV NP/nucleoprotein (CTELKLSDY), IAV PB1/polymerase basic protein 1 (VSDGGPNLY), HAdV-11 capsid L3/hexon protein (LTDLGQNLLY), SARS-CoV-2 3a/ORF3a (FTSDYYQLY) as well as tumor peptide antigens including MAGE1 (EADPTGHSY), MAGEA3 (EVDPIGHLY) and WT1 (TSEKRPFMCAY), all having in common a canonical motif with a negatively charged Asp or Glu residue at position 3 and a Tyr anchor residue at the C-terminus (PubMed : 1402688, PubMed : 17189421, PubMed : 19177349, PubMed : 20364150, PubMed : 24395804, PubMed : 25880248, PubMed : 26758806, PubMed : 30530481, PubMed : 32887977, PubMed : 7504010). A number of HLA-A*01 : 01-restricted peptides carry a post-translational modification with oxidation and N-terminal acetylation being the most frequent (PubMed : 25880248). Fails to present highly immunogenic peptides from the EBV latent antigens (PubMed : 18779413).. Allele A*02 : 01 : A major allele in human populations, presents immunodominant viral epitopes derived from IAV M/matrix protein 1 (GILGFVFTL), HIV-1 env (TLTSCNTSV), HIV-1 gag-pol (ILKEPVHGV), HTLV-1 Tax (LLFGYPVYV), HBV C/core antigen (FLPSDFFPS), HCMV UL83/pp65 (NLVPMVATV) as well as tumor peptide antigens including MAGEA4 (GVYDGREHTV), WT1 (RMFPNAPYL) and CTAG1A/NY-ESO-1 (SLLMWITQC), all having in common hydrophobic amino acids at position 2 and at the C-terminal anchors.. Allele A*03 : 01 : Presents viral epitopes derived from IAV NP (ILRGSVAHK), HIV-1 nef (QVPLRPMTYK), HIV-1 gag-pol (AIFQSSMTK), SARS-CoV-2 N/nucleoprotein (KTFPPTEPK) as well as tumor peptide antigens including PMEL (LIYRRRLMK), NODAL (HAYIQSLLK), TRP-2 (RMYNMVPFF), all having in common hydrophobic amino acids at position 2 and Lys or Arg anchor residues at the C-terminus (PubMed : 19543285, PubMed : 21943705, PubMed : 2456340, PubMed : 32887977, PubMed : 7504010, PubMed : 7679507, PubMed : 9862734). May also display spliced peptides resulting from the ligation of two separate proteasomal cleavage products that are not contiguous in the parental protein (PubMed : 27049119).. Allele A*11 : 01 : Presents several immunodominant epitopes derived from HIV-1 gag-pol and HHV-4 EBNA4, containing the peptide motif with Val, Ile, Thr, Leu, Tyr or Phe at position 2 and Lys anchor residue at the C-terminus. Important in the control of HIV-1, EBV and HBV infections (PubMed : 10449296). Presents an immunodominant epitope derived from SARS-CoV-2 N/nucleoprotein (KTFPPTEPK) (PubMed : 32887977).. Allele A*23 : 01 : Interacts with natural killer (NK) cell receptor KIR3DL1 and may contribute to functional maturation of NK cells and self-nonself discrimination during innate immune response.. Allele A*24 : 02 : Presents viral epitopes derived from HIV-1 nef (RYPLTFGWCF), EBV lytic- and latent-cycle antigens BRLF1 (TYPVLEEMF), BMLF1 (DYNFVKQLF) and LMP2 (IYVLVMLVL), SARS-CoV nucleocapsid/N (QFKDNVILL), as well as tumor peptide antigens including PRAME (LYVDSLFFL), all sharing a common signature motif, namely an aromatic residue Tyr or Phe at position 2 and a nonhydrophobic anchor residue Phe, Leu or Iso at the C-terminus (PubMed : 12393434, PubMed : 20844028, PubMed : 24192765, PubMed : 9047241). Interacts with natural killer (NK) cell receptor KIR3DL1 and may contribute to functional maturation of NK cells and self-nonself discrimination during innate immune response (PubMed : 17182537, PubMed : 18502829).. Allele A*26 : 01 : Presents several epitopes derived from HIV-1 gag-pol (EVIPMFSAL, ETKLGKAGY) and env (LVSDGGPNLY), carrying as anchor residues preferentially Glu at position 1, Val or Thr at position 2 and Tyr at the C-terminus.. Allele A*29 : 02 : Presents peptides having a common motif, namely a Glu residue at position 2 and Tyr or Leu anchor residues at the C-terminus.. Allele A*32 : 01 : Interacts with natural killer (NK) cell receptor KIR3DL1 and may contribute to functional maturation of NK cells and self-nonself discrimination during innate immune response.. Allele A*68 : 01 : Presents viral epitopes derived from IAV NP (KTGGPIYKR) and HIV-1 tat (ITKGLGISYGR), having a common signature motif namely, Val or Thr at position 2 and positively charged residues Arg or Lys at the C-terminal anchor.. Allele A*74 : 01 : Presents immunodominant HIV-1 epitopes derived from gag-pol (GQMVHQAISPR, QIYPGIKVR) and rev (RQIHSISER), carrying an aliphatic residue at position 2 and Arg anchor residue at the C-terminus. May contribute to viral load control in chronic HIV-1 infection.
See full target information HLA-A

Publications (19)

Recent publications for all applications. Explore the full list and refine your search

Frontiers in neurology 14:1113404 PubMed37228411

2023

Increased expression of cell adhesion molecules in myofasciitis.

Applications

Unspecified application

Species

Unspecified reactive species

Xue Ma,Huajie Gao,Li Xu,Zhuajin Bi,Suqiong Ji,Bitao Bu

Frontiers in immunology 14:1142862 PubMed37187745

2023

Immune desert in MMR-deficient tumors predicts poor responsiveness of immune checkpoint inhibition.

Applications

Unspecified application

Species

Unspecified reactive species

Guoxing Zheng,Yingsi Lu,Zheng Yang,Hong Chen,Qian Liang,Qingqing Zhu,Yan Li,Xing Xiao,Zhuzhen He,Yifan Zhu,Bo Li,Leilei Huang,Nan Dong,Shuang Hu,Yihang Pan,Changhua Zhang,Chengming Zhu

microPublication biology 2023: PubMed36743451

2023

A chemical screen underscores the essential role of STAT1-dependent IFNγ signaling to regulate HLA-I expression in cancer cells.

Applications

Unspecified application

Species

Unspecified reactive species

Myriam Barz,Bartlomiej Porebski,Pranauti Panshikar,Maria Häggbladd,Daniela Hühn,Oscar Fernandez-Capetillo

Journal of immunology (Baltimore, Md. : 1950) 207:493-504 PubMed34215653

2021

Proteolysis-Targeting Chimeras Enhance T Cell Bispecific Antibody-Driven T Cell Activation and Effector Function through Increased MHC Class I Antigen Presentation in Cancer Cells.

Applications

Unspecified application

Species

Unspecified reactive species

Vittoria Massafra,Sofia Tundo,Aline Dietzig,Axel Ducret,Christian Jost,Christian Klein,Roland E Kontermann,Hendrik Knoetgen,Martin Steegmaier,Andrea Romagnani,Yvonne A Nagel

Journal of the American Society of Nephrology : JASN 31:2705-2724 PubMed32900843

2020

Extracellular Matrix Injury of Kidney Allografts in Antibody-Mediated Rejection: A Proteomics Study.

Applications

Unspecified application

Species

Unspecified reactive species

Sergi Clotet-Freixas,Caitriona M McEvoy,Ihor Batruch,Chiara Pastrello,Max Kotlyar,Julie Anh Dung Van,Madhurangi Arambewela,Alex Boshart,Sofia Farkona,Yun Niu,Yanhong Li,Olusegun Famure,Andrea Bozovic,Vathany Kulasingam,Peixuen Chen,S Joseph Kim,Emilie Chan,Sajad Moshkelgosha,Syed Ashiqur Rahman,Jishnu Das,Tereza Martinu,Stephen Juvet,Igor Jurisica,Andrzej Chruscinski,Rohan John,Ana Konvalinka

Viruses 12: PubMed32276457

2020

HIV Reactivation in Latently Infected Cells With Virological Synapse-Like Cell Contact.

Applications

Unspecified application

Species

Unspecified reactive species

Toshiki Okutomi,Satoko Minakawa,Riku Hirota,Koko Katagiri,Yuko Morikawa

Journal of virology 94: PubMed31915283

2020

Two Functional Variants of AP-1 Complexes Composed of either γ2 or γ1 Subunits Are Independently Required for Major Histocompatibility Complex Class I Downregulation by HIV-1 Nef.

Applications

Unspecified application

Species

Unspecified reactive species

Lucas A Tavares,Julianne V de Carvalho,Cristina S Costa,Roberta M Silveira,Andreia N de Carvalho,Eduardo A Donadi,Luis L P daSilva

Theranostics 9:5105-5121 PubMed31410204

2019

Enrichment of CD146 Adipose-Derived Stem Cells in Combination with Articular Cartilage Extracellular Matrix Scaffold Promotes Cartilage Regeneration.

Applications

Unspecified application

Species

Unspecified reactive species

Xu Li,Weimin Guo,Kangkang Zha,Xiaoguang Jing,Mingjie Wang,Yu Zhang,Chunxiang Hao,Shuang Gao,Mingxue Chen,Zhiguo Yuan,Zhenyong Wang,Xueliang Zhang,Shi Shen,Haojiang Li,Bin Zhang,Hai Xian,Yuan Zhang,Xiang Sui,Ling Qin,Jiang Peng,Shuyun Liu,Shibi Lu,Quanyi Guo

Frontiers in immunology 9:167 PubMed29456541

2018

IFN-τ Mediated Control of Bovine Major Histocompatibility Complex Class I Expression and Function the Regulation of bta-miR-148b/152 in Bovine Endometrial Epithelial Cells.

Applications

Unspecified application

Species

Unspecified reactive species

Haichong Wu,Kangfeng Jiang,Shuai Guo,Jing Yang,Gan Zhao,Changwei Qiu,Ganzhen Deng

Frontiers in microbiology 8:2564 PubMed29312244

2017

Quantitative Analysis of Cellular Proteome Alterations in CDV-Infected Mink Lung Epithelial Cells.

Applications

Unspecified application

Species

Unspecified reactive species

Mingwei Tong,Li Yi,Na Sun,Yuening Cheng,Zhigang Cao,Jianke Wang,Shuang Li,Peng Lin,Yaru Sun,Shipeng Cheng
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com